GLP-1 exerts a particularly beneficial effect on the reduction in visceral fat, which is significant in the treatment of various metabolic disorders, including obesity, type 2 diabetes and non-alcoholic fatty liver disease. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatotic liver disease.